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Supplementary Note 1 
 
The following calculation shows how we converted Hartree units (Ha) (atomic units of 
energy) into binding energy (kcal/mol) for Mg2+ interacting with its binding site in the NMDAR 
channel. Note 1 Ha = 627.509 kcal/mol. 
For the coordination of Mg2+ by the NMDAR channel asparagines, we calculated the 
following energies at 298.15 K: 
For the octahedral coordination of Mg2+ by 6 waters = -1490.865140 Ha 
 
For the 4 asparagine residues alone = -658.509131 Ha 
 
For a single water molecule = -76.426767 Ha.  
 
And for Mg2+ coordinated by the 4 asparagines and 2 water molecules = -1843.68261 Ha. 
 
 
By substituting these Ha values into the following equation we obtain the binding energy of 
Mg2+ coordinated by the asparagines: 
[Mg(Asn)4(H2O)2]2+ + 4H2O - 4Asn - [Mg(H2O)6]2+ = ΔGbind 
-1843.68261+ 4 x (-76.426767) - (-658.509131) - (-1490.865140) = -0.015407 Ha 
 
This can be converted to kcal/mol as follows: 
-0.015407 x 627.51 = -9.668047 kcal/mol.   
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This value represents the theoretical ∆G for binding for Mg2+ to the 4 asparagines. 
This value is also comparable to ∆G calculated from the trapping model for the wild-type 
GluN1-GluN2B which is -3.95 kcal/mol. This value was determined for Mg2+ coordination in 
the presence of permeant ions, Na+, K+ and Ca2+. The ∆G from the trapping model was 
calculated from; ∆G = RT ln K, where K is the Mg2+(0 mV) dissociation constant taken from 
Table 2, R= 1.987 cal.mol-1.K-1, and T = 293 K.  
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Supplementary Figure 1. Aligning the pore region for GluN1-GluN2B tetramers 
The TMD including the pore region of the GluN2B subunit is subjected to a root-
mean-standard deviation (RMSD) analysis between the Cα of our human NMDAR 
model and the Xenopus NMDAR PDB 4TLM. RMSD bar: blue = 0 (‘good fit’), white = 
5, orange = 10. For simplicity only three subunits are shown. 
 
  
Supplementary Fig 2: Locations and interactions of GluN2B missense 
mutations in the human NMDAR model  
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Supplementary Figure 2. Locations and interactions of GluN2B missense 
mutations in the human NMDAR model.  
(a) P553 is located in pre-M1, close to the –SYTANLAAF- motif (black, numbered 
amino acids shown) in M3 of the same subunit, which is also juxtaposed to the –
SYTANLAAF- motif in M3 from the adjacent GluN1 subunit (orange, amino acids 
shown in single letter format). (b) The P553L substitution may disrupt receptor gating 
via interactions between L553 and N649 and/or L650 of the –SYTANLAAF- motif 
(1.7Å and 3.4Å). (c-e) C461 is located in the S1 domain of the LBD, but is not 
involved in the direct binding of glutamate. The C461F substitution could engage in 
van-der-Waal interactions with neighbouring residues in S1 of the same subunit 
(e.g., V417 and L465) or aromatic interactions with the neighbouring F529. The 
distance between F461 and the three neighbouring residues is ~5Å. Note change in 
the viewing angle from d to e. (f) V618, located in the ion channel, interacts with 
neighbouring hydrophobic residues via van der Waal interactions: L608 (in M2 of 
GluN2B, 4.8Å), V602 (in M2-M3 linker of GluN2B, 3.8Å), F609 (in M1 of GluN1, 
4.1Å), M634 (in M3 of GluN1; 4.3Å) and V613 (in M2 of GluN1, 5.0Å). 
 
  
Supplementary Fig. 3  Glutamate sensitivity of GluN2B 
mutants 
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Supplementary Figure 3. Glutamate sensitivity of GluN2B mutants 
(a) Membrane currents activated by a range of glutamate concentrations co-applied 
with 10 μM glycine in wild-type (WT) GluN1-GluN2B receptors and C461F, P553L, 
N615I or V618G GluN2B mutants. Cells were voltage clamped at -30 mV. (b) 
Primary sequence alignment for human ionotropic GluRs in pre-M1. P553 in GluN2B 
(blue, boxed) is highly conserved across the receptor family. (c) Current densities 
determined from whole-cell recording from HEK293 cells expressing WT and mutant 
GluN1-GluN2B NMDARs. Individual membrane currents elicited by saturating 
glutamate concentrations (-30 mV) were normalised to the cell capacitance. Mean 
values are shown by a red diamond. GluN2BWT: -20.36 ± 4.54 pA/pF (n = 18); 
GluN2BC461F: -6.49 ± 3.94 (n = 7); GluN2BP553L: -15.31 ± 3.70 (n = 15); GluN2BN615I: -
19.19 ± 3.24 (n = 13); GluN2BV618G: -17.55 ± 3.35 (n = 20). Data analysed using a 
one-way ANOVA with Dunnett's post-hoc test, * p < 0.05.  
 
  
Supplementary Fig 4. Mg2+ coordination site and its disruption by NMDA channel 
mutants  
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Supplementary Figure 4. Mg2+ coordination site and its disruption by NMDA 
channel mutants 
(a) Root-mean-standard deviation (RMSD) analysis of the TMD between the Cα of 
our human NMDAR model and the Xenopus PDB 4TLM reproduced from 
Supplementary Fig. 1. RMSD bar: blue= 0 (‘good fit’), white= 5, orange= 10, black 
(unaligned regions). Here, Mg2+ is included in the channel and shown as a black 
sphere. (b) Membrane currents elicited by 10 μM glutamate and 10 μM glycine at 
different Mg2+ concentrations in HEK293 cells transfected with GluN1 and GluN2B 
subunits (WT, N615I or V618G) voltage clamped at -60 mV. GluN1-GluN2BWT 
receptors are inhibited by Mg2+, whereas GluN1-GluN2BN615I and GluN1-
GluN2BV618G are insensitive to Mg2+ block. Calibrations apply to all currents. (c) The 
N615I substitution disrupts H-bonding between GluN2BN615I and GluN1N616. These 
H-bonds are critical for stabilizing the coordination of Mg2+ by the two sets of 
GluN1N616 and GluN2BN616 residues. 
 
  
Supplementary Fig. 5 Trapping model applied to Mg2+ block  
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Supplementary Figure 5. Trapping model applied to Mg2+ block 
(a) I-V relationships for GluN1-GluN2BWT in Krebs solutions with 0 Mg2+ using a 
voltage step protocol (from -90 to +90 mV) elicited by 10 μM glutamate and 10 μM 
glycine in Krebs solution with nominally 0 Mg2+. Experimental data are shown as 
symbols (mean ± s.e.m.), the curves were generated by the trapping model. (b) 
Schematic representation of Mg2+ binding in the NMDAR channel.  A single Mg2+ ion 
can approach the binding site from either the inside (i) or outside (o) surface of the 
membrane with forward and backward rate constants k+b and k-b) as indicated. (c) 
Table of predicted association and dissociation rate constants for Mg2+ binding and 
unbinding to the NMDAR channel. A single set of Mg2+ block and permeation rate 
constants consistent with the observed data for both wild-type and mutant receptors 
were used for both the trapping block model and permeation model. (d) Permeation 
model association rates for Na+ and K+ were constrained to be equal, while for Ca2+ 
permeation these rates were varied to allow matching of the currents in high calcium 
solution for wild-type, N615I and V618 mutant NMDARs. (e) Table of I-V relationship 
parameters for glutamate currents in the presence and absence of Mg2+ and/or 
memantine. These values were determined by fitting the trapping model to the 
experimental I-V data. 
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Supplementary Figure 6. Memantine inhibition of GluN1-GluN2B receptors 
(a) Membrane currents elicited by 10 μM glutamate and 10 μM glycine at different 
memantine concentrations (μM) in HEK293 cells (at -30 mV) expressing WT and 
mutant GluN1-GluN2B receptors. (b) Molecular docking of memantine in the GluN1-
GluN2BN615I receptor results in two defined binding clusters: one cluster (pose 1) is 
located just above the channel pore (coincident with the binding position noted in the 
WT receptor, see Fig. 4); the other (pose 2) is characterised by displacement of 
memantine to a cavity between the M2 and M3 helices. (c) Memantine docking in a 
GluN1-GluN2B structure with bound Mg2+ in situ: the docked Mg2+ ion laterally 
displaces memantine from the preferred binding site (pose 1; the 10 highest ranked 
memantine poses are shown) that is characterised by hydrophobic residues. (d) The 
displaced binding site for memantine is shown in relation to the transmembrane 
domain. The lipid bilayer is present for illustrative purposes. The human GluN1-
GluN2B receptor model was superimposed on the PDB 4TLM embedded in the 
plasma membrane from MEMprot (http://memprotmd.bioch.ox.ac.uk/). (e) 
Deactivation time constants (τ) determined with varying memantine concentrations. 
Decay kinetics were described by a single exponential following the removal of co-
applied 10 μM glutamate + 10 μM glycine alone and with a range of memantine 
concentrations. Memantine did not affect deactivation time for GluN1-GluN2BWT, 
GluN1-GluN2BN615I and GluN1-GluN2BV618G.  
 
 
  
Supplementary Fig. 7  Properties of evoked EPSCs 
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Supplementary Figure 7. Properties of evoked EPSCs 
(a) Evoked EPSCs (Vh -70 mV) in Krebs supplemented with 10 μM CNQX, 20 μM 
bicuculline and 10 μM D-serine, are blocked by 20 μM D-APV, indicating they are 
mediated by NMDARs. (b) Krebs containing 1.2 mM Mg2+ inhibits the evoked EPSCs 
at -70 mV holding potential but not at +40 mV, consistent with the Mg2+ voltage-
dependent block of NMDARs. Upper paired traces: evoked EPSCs at -70 and +40 
mV in 0 Mg2+; middle traces: evoked EPSCs in 1.2 mM Mg2+ at the same holding 
potentials; lower traces: evoked EPSCs following re-perfusion with 0 Mg2+ Krebs. 
Calibration values apply to all traces. 
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Supplementary Fig. 8. Comparison of evoked EPSCs between 
untransfected and wild-type GluN2B transfected neurons  
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Supplementary Figure 8. Comparison of evoked EPSCs between untransfected 
and wild-type GluN2B transfected neurons 
(a) Bar graph comparing the mean peak EPSC amplitude between untransfected 
(DIV 13-16) and wild-type GluN2B cDNA transfected neurons (DIV 13-16). (b) 
Comparison of the mean EPSC weighted decay time constant for untransfected and 
wild-type GluN2B cDNA transfected neurons. Number of cells: untransfected; 19, 
transfected; 25.  
 
 
 
 
 
  
Residue 
 
Phenotype 
 
SIFTa 
 
Polyphen-2b 
 
Mutation 
tasterc 
 
Ref 
 
L825V Autism  Tolerated: 0.12 Prob. damaging: 1.000 Disease causing 1 
A590T*(1) 
R682C 
A1267S*(2) 
M1331I* (1) 
Phenotype? 
Moderate ID 
Phenotype? 
Phenotype? 
Tolerated: 0.18 
Damaging: 0 
Tolerated: 0.45 
Tolerated: 0.2 
Prob.damaging: 0.987 
Prob.damaging: 1.000 
Benign: 0.000 
Benign: 0.000 
Disease causing 
Disease causing 
Polymorphism 
Disease causing 
2 
C461F LGS Damaging: 0 Prob. damaging: 1.000 Disease causing 3 
A636P Mild ID Damaging: 0 Prob. damaging: 1.000 Disease causing  4 
p.P553L Severe ID Damaging: 0 Poss. damaging: 0.951 Disease causing 5 
p.C456Y  Autism Damaging: 0 Prob. damaging: 1.000 Disease causing 6 
p.V618G  
p.N615I  
p.R540H  
West syndrome 
West syndrome 
West syndrome 
Damaging: 0 
Damaging: 0 
Damaging: 0 
Prob. damaging: 1.000 
Prob. damaging: 1.000 
Prob. damaging: 0.999 
Disease causing 
Disease causing 
Disease causing 
7 
p.R1110C* (1) Phenotype? Tolerated: 0.17 Prob. damaging: 0.998 Disease causing 8 
Supplementary Table 1. Bioinformatic analyses of GluN2B missense mutations.  
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Supplementary Table 1. Bioinformatics analyses of GluN2B missense 
mutations  
Data indicate the likelihood of GluN2B missense mutations causing disease as 
predicted by bioinformatics software. The scores indicate various categories of 
potential disease association: aSIFT: Damaging mutations are scores ≤0.05; 
Tolerated mutation = 0.05 ≤ score ≤ 1; bPolyphen-2: Probably damaging = 0.957 ≤ 
score ≤ 1; Possibly damaging = 0.447 ≤ score ≤0.956; Benign = score <0.447; 
cMutation Taster: mutations are either classified as: “polymorphism” or “disease 
causing”. For Phenotype, the ‘phenotype ?’ category is used when the citation does 
not explicitly denote the phenotype of the subject presenting the mutant. ID indicates 
intellectual disability; LGS is the Lennox-Gastaut syndrome. Amino acid substitutions 
shown in blue are those that we selected for functional screening. * indicates when 
the same amino acid substitution has been found in the 1000 Genome 1000 
database http://www.internationalgenome.org/home, together with the number of 
subjects presenting with the same substitutions (n).  
 
  
Variant Location Glutamate potency (µM) 
Current 
density 
(pA/pF) 
Ri (MΩ) 
Patient 
phenotype 
WT - 7.18 ± 0.82 -20.36 ± 4.54  27.04 ± 10.09 - 
C456Y S1 - - - Autism 
C461F S1 511.4 ± 55.49****** -6.49 ± 3.94** 36.44 ± 32.53a 
LGS with 
autistic 
features 
R540H S1-M1 3.17 ± 1.31* -30.31 ± 7.71 18.86 ± 6.22 WS 
P553L Pre-M1 12.67 ± 2.01* -15.31 ± 3.70 b Severe ID 
N615I M2-M3 9.15 ± 1.23 -19.19 ± 3.24 1.33 ± 0.15*** WS 
V618G M2-M3 6.08 ± 1.43 -17.55 ± 3.35 1.46 ± 0.99*** WS 
A636P M3 - - - Mild ID 
R682C M3-S2 8.64 ± 1.22 -15.34 ±  2.56  7.38 ± 3.21 Moderate ID 
L825V M4 7.66 ± 1.25 -19.06 ± 3.65 17.99 ± 4.20 Autism 
Supplementary Table 2.  Screening missense mutations of GluN2B 
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Supplementary Table 2. Screening missense mutations of GluN2B 
Functional and clinical parameters for nine GluN2B subunit missense mutations. 
These mutants were selected from Table 1 for screening of their functional 
properties by electrophysiology, following expression as GluN1-GluN2B 
diheteromers in HEK293 cells. Glutamate potency (μM) is determined at -30 mV in 
the presence of 10 μM glycine and measured from the EC50s from curve fits to 
glutamate concentration response curves. The glutamate current density (pA/pF) is 
determined from the maximal glutamate current at -30 mV which is normalised to cell 
capacitance. The rectification index (Ri) is measured from the current-voltage 
relationships in 1.2 mM Mg2+ for responses induced by 3 μM glutamate and 10 μM 
glycine by determining the ratio of current evoked by glutamate at +60 /-60 mV. LGS 
– Lennox-Gastaut syndrome; WS - West syndrome; ID - intellectual disability. a300 
μM glutamate was used for determining Ri due to the significant decrease in 
glutamate potency of receptors incorporating GluN2BC461F. bThe I-V plot was not 
determined due to small steady-state currents. NMDARs containing GluN2BP553L 
resulted in pronounced desensitizing currents. No glutamate current was detected 
for GluN1-GluN2BC456Y and GluN1-GluN2BA636P up to 3 mM glutamate. * 
p<0.05; ** p<0.01; *** p<0.005; ****p<0.001; ***** p<0.0005; ****** p<0.0001. 
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